Cidara Therapeutics Inc (CDTX) receives a Buy rating from H.C. Wainwright

NUE

Cidara Therapeutics Inc’s filing revealed that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $100.0 million on Jun 26 ’25. In the deal valued at $44.00 per share,2,272,727 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,365,523 shares worth roughly $162.55 million.

Then, Mineo Chrysa bought 2,270 shares, generating $49,281 in total proceeds. Upon buying the shares at $21.71, the Director now owns 2,270 shares.

Before that, Mineo Chrysa bought 1,050 shares. Cidara Therapeutics Inc shares valued at $24,614 were divested by the Director at a price of $23.44 per share. As a result of the transaction, Mineo Chrysa now holds 3,320 shares, worth roughly $0.16 million.

A number of analysts have revised their coverage, including Citizens JMP’s analysts, who began to cover the stock in mid March with a ‘”a Mkt outperform”‘ rating. RBC Capital Mkts started covering the stock on December 13, 2024. It rated CDTX as “an Outperform”.

Price Performance Review of CDTX

On Monday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock fall -0.98% to $48.3. Over the last five days, the stock has lost -2.33%. Cidara Therapeutics Inc shares have risen nearly 304.86% since the year began. Nevertheless, the stocks have risen 79.69% over the past one year. While a 52-week high of $56.83 was reached on 06/24/25, a 52-week low of $10.14 was recorded on 04/07/25.

Levels Of Support And Resistance For CDTX Stock

The 24-hour chart illustrates a support level at 46.42, which if violated will result in even more drops to 44.54. On the upside, there is a resistance level at 49.35. A further resistance level may holdings at 50.39.

How much short interest is there in Cidara Therapeutics Inc?

A steep rise in short interest was recorded in Cidara Therapeutics Inc stocks on 2025-06-13, growing by 0.2 million shares to a total of 0.65 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 0.45 million shares. There was a rise of 31.31%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on November 08, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.